Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Image
  • Published:

Infographic: bevacizumab eliminates the angiogenic threat of retinopathy of prematurity (BEAT-ROP study)

Eye (2026)Cite this article

Subjects

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Retinopathy of prematurity (ROP) is a disorder in preterm infants driven primarily by vascular endothelial growth factor, leading to pathological neovascularisation, triggering retinal detachment if untreated.

Reference

  1. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Anjali Agrawal, Anil Babanrao Gangwe.

Authors and Affiliations

  1. Department of Ophthalmology, District Hospital Baloda Bazar, Chhattisgarh, India

    Anjali Agrawal & Rajesh Awasthi

  2. Vitreo-Retina Services, MGM Eye Institute, Raipur, India

    Anil Babanrao Gangwe

Authors
  1. Anjali Agrawal
    View author publications

    Search author on:PubMed Google Scholar

  2. Anil Babanrao Gangwe
    View author publications

    Search author on:PubMed Google Scholar

  3. Rajesh Awasthi
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Concept, design, definition of intellectual content: A.A., A.B.G., and R.A.; Manuscript preparation, manuscript editing, and manuscript review: A.A., A.B.G., and R.A. The manuscript has been read and approved by all authors.

Corresponding author

Correspondence to Anjali Agrawal.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agrawal, A., Gangwe, A.B. & Awasthi, R. Infographic: bevacizumab eliminates the angiogenic threat of retinopathy of prematurity (BEAT-ROP study). Eye (2026). https://doi.org/10.1038/s41433-026-04285-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41433-026-04285-8

Search

Advanced search

Quick links